{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T16:32:24Z","timestamp":1768149144247,"version":"3.49.0"},"reference-count":98,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2022,4,16]]},"DOI":"10.1080\/10428194.2021.2010068","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T08:45:15Z","timestamp":1638434715000},"page":"1020-1033","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":17,"title":["Novel therapeutics and targets in myelofibrosis"],"prefix":"10.1080","volume":"63","author":[{"given":"Julian A.","family":"Waksal","sequence":"first","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire N.","family":"Harrison","sequence":"additional","affiliation":[{"name":"Guys\u2019 and St. Thomas\u02bc NHS Foundation Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John O.","family":"Mascarenhas","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,12,2]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25230"},{"issue":"2","key":"CIT0002","first-page":"121","volume":"16","author":"O'Sullivan JM","year":"2018","journal-title":"Clin Adv Hematol Oncol"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0175-y"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-579136"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.3"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.275"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M600064200"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2008.02.009"},{"issue":"4","key":"CIT0009","first-page":"CD010298","author":"Mart\u00ed-Carvajal AJ","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.119545"},{"key":"CIT0011","first-page":"S203","volume":"324611","author":"Harrison C","year":"2021","journal-title":"EHA Library"},{"key":"CIT0012","first-page":"4197","volume":"130","author":"Claire N","year":"2017","journal-title":"Blood"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3194-4"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13892-x"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32664"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2020.1741381"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-783225"},{"key":"CIT0018","unstructured":"Ruxolitinib [package insert]. Wilmington (DE): Incyte Corporation; 2011."},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13005"},{"key":"CIT0020","unstructured":"Fedratinib [package insert]. Summit (NJ); Celgene Corporation; 2019."},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.1590"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-740092"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.4418"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30237-5"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.71"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-135872"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2435-7"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.2147\/JEP.S110702"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-484832"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30027-3"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5818"},{"issue":"23","key":"CIT0032","first-page":"5929","volume":"4","author":"Tremblay D","year":"2020","journal-title":"Blood Adv"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003314"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1038\/nature09504"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2017.06.004"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12282"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1038\/nature09589"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.03.024"},{"key":"CIT0039","unstructured":"Talpaz M, Rampal RK, Verstovsek S. CPI-0610, a bromodomain and extraterminal domain protein (BET) inhibitor, as monotherapy in advanced myelofibrosis patients refractory\/intolerant to JAK inhibitor: update from phase 2 MANIFEST study. Presented at American Society of Hematology Annual Conference; 2020. Abstract 2163. Session 634."},{"key":"CIT0040","doi-asserted-by":"crossref","unstructured":"Mascarenhas J, Harrison C, Patriarca A. CPI-0610, a bromodomain and extraterminal domain protein (BET) inhibitor, in combination with Ruxolitinib, in JAK-inhibitor-na\u00efve myelofibrosis patients: update of MANIFEST phase 2 study. Presented at American Society of Hematology Annual Meeting; 2020. Abstract 55. Session 634.","DOI":"10.1182\/blood-2019-128211"},{"key":"CIT0041","first-page":"EP1080","volume":"324803","author":"Keller P","year":"2021","journal-title":"EHA Library"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.1471"},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.11.009"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.031682"},{"key":"CIT0045","unstructured":"Venetoclax (venclexta) [package insert]. Chicago (IL): Abbvie Inc. 2016."},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-5-2"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136938"},{"key":"CIT0048","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2011.313"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203464"},{"key":"CIT0050","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.12.8945"},{"key":"CIT0051","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-410712"},{"key":"CIT0052","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018893545"},{"key":"CIT0053","unstructured":"Mascarenhas J, Higgins B, Anders D. Safety and efficacy of Idasanutlin in patients with hydroxyurea-resistant\/intolerant polycythemia vera: results of an international phase II study. American Society of Hematology National Conference; 2020. Oral Presentation, session 634. Abstract 479."},{"key":"CIT0054","unstructured":"Al-Ali HK, Delgado RG, Lange A. A first-in-class, murine double minute 2 inhibitor (MDM2i) for myelofibrosis relapsed or refractory to janus associated kinase inhibitor treatment. European Hematology Association Annual Meeting; 2020, abstract S215."},{"key":"CIT0055","author":"Owens TW","year":"2013","journal-title":"J Carcinog Mutagen"},{"key":"CIT0056","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)00008-8"},{"key":"CIT0057","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-019-0157-6"},{"key":"CIT0058","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003829"},{"key":"CIT0059","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2013.07.011"},{"key":"CIT0060","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-330563"},{"key":"CIT0061","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.209965"},{"key":"CIT0062","doi-asserted-by":"crossref","unstructured":"Yacoub A, Wang ES, Rampal RR. Addition of parsaclisib (INCB050465), a PI3K\u03b4 inhibitor, in patients with suboptimal response to Ruxolitinib: a phase 2 study in patients with myelofibrosis. Presented at: 2021 AACR Annual Meeting 2021; April 10\u201315; 2021. Virtual. Abstract CT162.","DOI":"10.1158\/1538-7445.AM2021-CT162"},{"key":"CIT0063","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2015.05.017"},{"key":"CIT0064","doi-asserted-by":"publisher","DOI":"10.1177\/0192623320966238"},{"issue":"13","key":"CIT0065","first-page":"1563","volume":"75","author":"Zvereva MI","year":"2010","journal-title":"Biochemistry"},{"key":"CIT0066","doi-asserted-by":"publisher","DOI":"10.1126\/science.1689074"},{"key":"CIT0067","doi-asserted-by":"publisher","DOI":"10.1038\/345458a0"},{"key":"CIT0068","doi-asserted-by":"publisher","DOI":"10.1126\/science.7605428"},{"key":"CIT0069","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018022012"},{"key":"CIT0070","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310523"},{"key":"CIT0071","unstructured":"Geron announces removal of full clinical hold on Imetelstat IND [cited 2014 Nov 3]. Available from: https:\/\/ir.geron.com\/investors\/press-releases\/press-release-details\/2014\/Geron-Announces-Removal-of-Full-Clinical-Hold-on-Imetelstat-IND\/default.aspx"},{"key":"CIT0072","unstructured":"Mascarenhas J, Komrokji R, Cavo M. Telomerase activity, telomere length and hTERT expression correlate with clinical outcomes in higher-risk myelofibrosis (MF) relapsed\/refractory (R\/R) to janus kinase inhibitor treated with Imetelstat. Abstract 347. Session 634. Presented at American Society of Hematology National Conference; 2020."},{"key":"CIT0073","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02864"},{"key":"CIT0074","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3000111"},{"key":"CIT0075","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009683"},{"key":"CIT0076","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00850-2015"},{"key":"CIT0077","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.6.4035"},{"key":"CIT0078","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-115362"},{"key":"CIT0079","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000561592.51072.9b"},{"key":"CIT0080","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.157"},{"key":"CIT0081","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-569525"},{"key":"CIT0082","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.03.014"},{"key":"CIT0083","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000054"},{"key":"CIT0084","doi-asserted-by":"crossref","unstructured":"Yacoub A, Pettit KM, Bradley TJ. A phase 2 study of the LSD1 inhibitor IMG7289 (bomedemstat) for the treatment of advanced myelofibrosis. Presented at American Society of Hematology National Conference; December 2020. Session 634. Abstract 51.","DOI":"10.1182\/blood-2019-123244"},{"key":"CIT0085","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2019.02.010"},{"key":"CIT0086","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1356"},{"key":"CIT0087","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04618-5"},{"key":"CIT0088","doi-asserted-by":"crossref","unstructured":"Hobbs GS, Bozkus CC, Wadleigh M. Results of a phase II study of PD-1 inhibition in advanced myeloproliferative neoplasms. Abstract 2162. Session 634. Presented at American Society of Hematology National Conference; 2020.","DOI":"10.1182\/blood-2020-137294"},{"key":"CIT0089","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.637420"},{"key":"CIT0090","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.280"},{"key":"CIT0091","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30236-4"},{"key":"CIT0092","unstructured":"Mosca M, Hermange G, Tisserand A, et\u00a0al. Inferring the dynamic of mutated hematopoietic stem and progenitor cells induced by IFNa in myeloproliferative neoplasms. Blood. 2021 Aug 18. Epub ahead of print. PMID: 34407546."},{"key":"CIT0093","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.235648"},{"key":"CIT0094","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-131217"},{"key":"CIT0095","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2017.05.001"},{"key":"CIT0096","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4415"},{"key":"CIT0097","doi-asserted-by":"crossref","unstructured":"Mascarenhas J, Kosiorek HE, Varricchio L. Rationale for and results of a phase I study of the TGF-\u03b2 1\/3 inhibitor AVID200 in subjects with myelofibrosis: MPN-RC 118 trial. Presented at American Society of Hematology Conference; 2020. Session 634. Abstract 1254.","DOI":"10.1182\/blood-2020-140830"},{"key":"CIT0098","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-110381"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2021.2010068","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T15:23:18Z","timestamp":1657207398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2021.2010068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,2]]},"references-count":98,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,4,16]]}},"alternative-id":["10.1080\/10428194.2021.2010068"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2021.2010068","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-10-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}